Copyright
©The Author(s) 2015.
World J Gastrointest Pharmacol Ther. Nov 6, 2015; 6(4): 137-144
Published online Nov 6, 2015. doi: 10.4292/wjgpt.v6.i4.137
Published online Nov 6, 2015. doi: 10.4292/wjgpt.v6.i4.137
Formulations | Generic name | Proprietary names | Mode of delivery | Site of drug release |
Azo-bonded prodrugs | Sulfasalazine | Azulfidine®; Salazopyrin®; Pyralin® | Mesalazine bound to sulfapyridine | Colon |
Olsalazine | Dipentum® | Two mesalazine molecules bound together | Colon | |
Balsalazide | Colazide®; Colazal® | Mesalazine bound to 4-aminobenzoyl-β-alanine | Colon | |
pH dependent | Mesalazine | Asacol®; Mesren® | Eudragit-S coating (dissolves at pH ≥ 7) | Terminal ileum, colon |
Salofalk®; Mesasal®; Claversal® | Eudragit-L coating (dissolves at pH ≥ 6) | Mid ileum to colon | ||
Salofalk Granules® | Eudragit-L coating and matrix core | Mid ileum to colon | ||
Time dependent | Mesalazine | Pentasa®, Pentasa® granules | Microspheres encapsulated within an ethycellulose semi-permeable membrane | Duodenum to colon |
MMX | MMX mesalazine | Lialda®; Mezavant XL®; Mezavant® | Enteric coating (dissolves at pH ≥ 7). MMX of lipophilic and hydrophilic excipients | Terminal ileum and entire colon |
- Citation: Ye B, van Langenberg DR. Mesalazine preparations for the treatment of ulcerative colitis: Are all created equal? World J Gastrointest Pharmacol Ther 2015; 6(4): 137-144
- URL: https://www.wjgnet.com/2150-5349/full/v6/i4/137.htm
- DOI: https://dx.doi.org/10.4292/wjgpt.v6.i4.137